Black Diamond Therapeutics (BDTX) Net Cash Flow: 2019-2021
Historic Net Cash Flow for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to $19.2 million.
- Black Diamond Therapeutics' Net Cash Flow rose 188.90% to $19.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was $31.2 million, marking a year-over-year increase of 126.24%. This contributed to the annual value of -$19.8 million for FY2024, which is 191.78% down from last year.
- Latest data reveals that Black Diamond Therapeutics reported Net Cash Flow of $19.2 million as of Q4 2021, which was up 106.88% from $9.3 million recorded in Q3 2021.
- Black Diamond Therapeutics' 5-year Net Cash Flow high stood at $202.5 million for Q1 2020, and its period low was -$293.2 million during Q2 2020.
- Moreover, its 3-year median value for Net Cash Flow was $2.1 million (2019), whereas its average is $1.3 million.
- Data for Black Diamond Therapeutics' Net Cash Flow shows a peak YoY increase of 3,040.26% (in 2020) and a maximum YoY decrease of 5,685.46% (in 2020) over the last 5 years.
- Quarterly analysis of 3 years shows Black Diamond Therapeutics' Net Cash Flow stood at $76.0 million in 2019, then slumped by 128.41% to -$21.6 million in 2020, then surged by 188.90% to $19.2 million in 2021.
- Its last three reported values are $19.2 million in Q4 2021, $9.3 million for Q3 2021, and $23.2 million during Q2 2021.